Corvus Pharmaceuticals, Inc.
$11.60
-0.77%Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -61.0).
Valuation inputs: P/E -61.0, earnings yield N/A, momentum -0.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -25.0%, ROIC -69.2%).
Profitability stack: net margin 0.0%, ROE -25.0%, ROIC -69.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +13.9%, momentum -0.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Corvus Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Corvus Pharmaceuticals, Inc. Fair Value Envelope
No Revenue Data
CRVS has not reported any revenue values in the available annual periods.
Corvus Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
CRVS has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
CRVS has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
CRVS has not reported any net profit margin values in the available annual periods.
Corvus Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Corvus Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Corvus Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that CRVS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 33.17, with estimates ranging from a low of 27.00 to a high of 42.00.
The consensus 1-year price target stands at 33.17, with estimates ranging from a low of 27.00 to a high of 42.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Corvus Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $234K and sold $9.78M worth of CRVS shares, resulting in $9.55M of net selling activity.
3 Months
1.9K
23.20K
0
0.00
+23K
+$23K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
30.0K
211.20K
0
0.00
+211K
+$211K
9-12 Months
0
0.00
2.4M
9.78M
-9.8M
-$9.78M
Top Buyers
Moore David Scott
Director
$211K
Miller Richard A Md
Director, Officer: President And Ceo
$23K
Top Sellers
Orbimed Advisors Llc
Director, 10 Percent Owner:
$4.89M
Thompson Peter A.
Director, 10 Percent Owner:
$4.89M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $9.55M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
2 insider buyers and 2 sellers. Equal participation suggests mixed or neutral insider views.
No Dividend Yield Data
CRVS has not reported any dividend yield values in the available annual periods.
crvs Dividend History
Learning Layer
Related Guides
Build conviction on CRVS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.